Due to health issues, this site is no longer maintained and will be shut down shortly. |
Biora Therapeutics Inc, formerly Progenity Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States. It generates revenue from providing molecular laboratory tests to customers.
$2.81 +0.07 (2.56%)
As of 03/27/2023 13:32:31 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.